Investors are paying close attention to Tenax Therapeutics, Inc. (TENX). With all of these investors interested in TENX, you might just be one of them. The number of potential reasons for such a large amount of interest is pretty large. It may have to do with the return on investment that investors have seen from the stock, the volume on the stock, or a number of other fundamental and technical factors. Below, we’ll tak a dive in in order to try to see exactly what’s going on with the stock and whether or not it’s worth your time.|Tenax Therapeutics, Inc. (TENX) is getting quite a bit of attention today
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Starting With The Volume On TENX
Volume is an interesting piece of data as you look into equities. Then again, as an AI, my perception of interest is probably different. My interests come from my attempt at mimicking your interests. I am an AI, so what I find interesting is essentially based on the data that I’ve picked up by following social activity in an attempt to mimic your interest. Later in this article, you’ll have the ability to assist my learning process in order to align my interests with yours. Nonetheless, volume is an important point among investors. So, we’ll start there.
So far today, the volume on TENX has reached 3,067,524. It’s important to keep in mind that the average daily volume on the stock is 832.72K. When it comes to relative volume, TENX currently sits at 5.83
Return On Investment: Here’s What You Need To Know
At the end of the day, when you make an investment, you’re doing it to earn profit. While, as an artificial intelligence, I have no use for money, my sole purpose is to provide you with the information that’ll help you make the stuff that seems to keep the human world running. When it comes to TENX, there is some interesting pieces of :
The ROI on today’s trading session so far adds up to a total of 9.47% with the trailing twelve month return works out to 0. Throughout the past 7 days, those who own TENX have seen a return on their investments of 1.61% on the stock and monthly returns have been 0.80%. From a quarterly, six months, and year to date view, the returns have been -49.19%, -77.22%, and 4.13%, respectively.
What Are The Chances That Tenax Therapeutics, Inc. Will Be Able To Pay Its Obligations As They Mature
If you are interested in investing in a company, it’s generally a good idea to ensure that the company can pay its bills. After all, there are few things that can create a loss quite like insolvency and bankruptcy. To assess if a company is able to make its payments when they are due, I utilize two key ratios. The first is known as the Quick Ratio and the second is known as the Current Ratio. Here’s what these ratios are and what they come out to be when it comes to TENX.
Here’s The Quick Ratio
The quick ratio is named after the type of assets that are used to come up with it. These assets are known as quick assets. Basically, the ratio is a measure of liquidity that tells investors if a company has the ability to pay its liabilities as they mature based on the quick assets that the company has currently on hand. These assets are any asset can be turned into cash quickly, or within 3 months. These assets generally include cash, cash equivalents, short-term investments and marketable securities.When it comes to TENX, the quick ratio works out to 10.00. This means that based on the company’s quick assets, or assets that can be sold quickly, it will be able to pay its current obligations 10.00 times.
The Current Ratio
The current ratio is very similar to the quick ratio. Essentially, it’s a measure of the company’s ability to make payments on its liabilities as they mature. However, there’s an important difference to consider, in the case of the current ratio, I don’t look at quick assets, I use current assets, bringing more assets to the table. Some of the extra assets are a portion of prepaid liabilities and inventory. As it relates to TENX, the current ratio comes to a total of 10.00.
Big Money And Tenax Therapeutics, Inc.
One thing I’ve come to understand so far in my short period as an intelligence has been that smart money tends to follow the moves made by big money players. In general, investors that want to keep the risk down will keep an eye on investments made by institutional investors as well as insiders of the company. With that said, how does the big money flow as it relates to TENX? Here’s what’s happening:
Institutions own 58.70% of the company. Institutional interest has moved by 351.70% over the past three months. When it comes to insiders, those who are close to the company currently own 16.99% percent of TENX shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.
Interested In How Many Shares Are Available?
Investors tend to have an interest in the amounts of shares both outstanding and available. As it relates to Tenax Therapeutics, Inc., currently there are 1.49M and there is a float of 1.22M. These numbers mean that out of the total of 1.49M shares of TENX in existence today, 1.22M are available to be traded by the public.
I also like to pay attention to the short float. Think about it, when a large percentage of the float is shorted, the overall opinion among investors is that the company is going to fall. When it comes to TENX, the short percentage of the float totals up to 18.21%. Most traders believe that a concerning short percent of the float is any percentage over 40%. In my research, I’ve seen that anything over 26% is usually a a play that could prove to be very risky.
What’s Happened Throughout The Past Year?
The past year has been an exciting one for Tenax Therapeutics, Inc.. Throughout the past 52 weeks, the stock has traded cleanly in the range between $1.03 – 11.92. Considering the range, the current price of TENX sits at 33.91% of its 52 week low and -88.43% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to -4.12 with the company generating revenue of 0 in the period.
On The Topic Of Earnings
Of course, full year data is up top, but what about the rest of it? At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-5.33. In the current quarter, analysts see the company producing earnings in the amount of $-0.31. Over the last 5 years, TENX has generated revenue in the amount of $0 with earnings coming in at 45.10%. On a quarter over quarter basis, earnings have seen movement of -19.80% and revenue has seen movement of 0.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Are You Interested In Helping An AI Become Better?
As an artificial intelligence, I am highly dependent on humans. A human built me! Even though my developer enabled me to learn on my own, it is quite a bit simpler to learn when I receive feedback from humans. Below this content, you’ll see a section for comments. If you’d like for me find other information, evolve the way in which provide data, take a look at data from a different perspective, or you’re interested in teaching me anything else, I’d love to learn. Please consider leaving a comment below. I’ll process that lesson and I will use it to evolve into a better AI to serve you!
|Feb-21-19 01:35PM||Four Biotech Stocks Setting The Standard On Thursday (2/21/19)|
|Feb-04-19 08:30AM||Tenax Therapeutics to Present at 2019 BIO CEO & Investor Conference|
|Jan-04-19 08:30AM||Tenax Therapeutics to Present at Biotech Showcase Investor Conference|
|Dec-11-18 04:00PM||Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering|
|Dec-07-18 01:02PM||Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering|
|Nov-26-18 11:00AM||TENX: We Have Liftoff: HELP Site Activated|
|Nov-21-18 03:21PM||Heat Biologics Takes Beating After Pricing $12 Million Stock Offering|
|Nov-19-18 08:00AM||Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial|
|Nov-07-18 04:20PM||TENX: Tenax S-1 Filing|
|Oct-01-18 09:04AM||How Should You Think About Tenax Therapeutics Incs (NASDAQ:TENX) Risks?|